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Available online 18 December 2018Background: DNA mismatch repair (MMR) defects are a major factor in colorectal tumorigenesis in Lynch
syndrome (LS) and 15% of sporadic cases. Some adenomas from carriers of inherited MMR gene mutations
have intact MMR protein expression implying other mechanisms accelerating tumorigenesis. We determined
roles of DNA methylation changes and somatic mutations in cancer-associated genes as tumorigenic events in
LS-associated colorectal adenomas with intact MMR.
Methods:We investigated 122 archival colorectal specimens of normalmucosae, adenomas and carcinomas from
57 LS patients. MMR-deficient (MMR-D, n=49) and MMR-proficient (MMR-P, n=18) adenomas were of par-
ticular interest and were interrogated bymethylation-specific multiplex ligation-dependent probe amplification
and Ion Torrent sequencing.
Findings: Promoter methylation of CpG island methylator phenotype (CIMP)-associated marker genes and
selected colorectal cancer (CRC)-associated tumor suppressor genes (TSGs) increased and LINE-1 methylation
decreased from normalmucosa toMMR-P adenomas toMMR-D adenomas. Methylation differences were statis-
tically significantwhen either adenoma groupwas comparedwith normalmucosa, but not betweenMMR-P and
MMR-D adenomas. Significantly increased methylation was found in multiple CIMP marker genes (IGF2,
NEUROG1, CRABP1, and CDKN2A) and TSGs (SFRP1 and SFRP2) inMMR-P adenomas already. Furthermore, certain
CRC-associated somatic mutations, such as KRAS, were prevalent in MMR-P adenomas.
Interpretation: We conclude that DNA methylation changes and somatic mutations of cancer-associated genes
might serve as an alternative pathway accelerating LS-associated tumorigenesis in the presence of proficientMMR.
Fund: Jane and Aatos Erkko Foundation, Academy of Finland, Cancer Foundation Finland, Sigrid Juselius Founda-
tion, and HiLIFE.










Lynch syndrome (LS) is a hereditary cancer predisposing syndrome
caused by germline defects in DNA mismatch repair (MMR) genes
MLH1, MSH2, MSH6 and PMS2 [1], or rarely deletions in the 3′ end of
EPCAM gene that lead to hypermethylation of MSH2 gene promoter
[2]. These germline defects cause a reduced level of MMR protein, i.e.d Clinical Genetics, P.O. Box 63
d.
Nevala).
pen access article under the CC BY-Nhaploinsufficiency, which accelerates the occurrence of de novo somatic
mutations [3] or compromises other functions of MMR genes, such
as apoptosis signaling [4], thereby increasing the risk for early onset
malignancies. Those defects together with epigenetic events cause an
increased risk of cancer [5], primarily colorectal cancer (CRC) and endo-
metrial cancer [6].
The “secondhit” leading to a loss of the remaining functional allele of
a MMR gene is typically caused by loss of heterozygosity (LOH) or so-
matic mutations [7–9]. However, MMR deficiency is thought to appear
as a secondary event in LS tumorigenesis, supported bymultiple studies
observing that 10–46% of adenomas show retained expression of MMRC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
Functional DNA mismatch repair is critical for cancer avoidance.
DNA mismatch repair genes comply with the Knudson's two-hit
paradigm for tumor suppressor genes. Lynch syndrome individ-
uals have inherited a mutant copy of a given DNAmismatch repair
gene whichmakes them susceptible to cancer, but as the product
of the remaining normal copy of the same gene is available, tumor
development is prevented. Tissues with an intact allele present
show normal expression of the respective mismatch repair pro-
tein. However, recent evidence reveals that 10–46%of colorectal
adenomas from Lynch syndrome patients retain mismatch repair
protein expression, yet a tumor has developed, implying that pro-
ficient mismatch repair alone is insufficient to prevent tumor initi-
ation. Molecular events needed in addition to or alternative to
deficient DNA mismatch repair to initiate tumorigenesis, as well
as the chronological sequence of events, is obscure. Deficient
mismatch repair is associatedwith a characteristic mutational sig-
nature consisting of instability at repeat sequences and a desig-
nated pattern of base substitutions. Utilization of such
mutational preferences to determine if a given alteration has oc-
curred before or after mismatch repair deficiency, together with
other approaches, has resulted in varying conclusions of early or
late appearance of mismatch repair defects in Lynch syndrome tu-
morigenesis. Based on the above cited and other (recent) literature
retrieved from PubMed, together with our previous observation
that a mismatch repair-proficient subset exists among adenomas
from a nation-wide registry of Lynch syndrome individuals, this
study was undertaken to explore the tumorigenic events in
Lynch syndrome-associated colorectal adenomas retaining MMR
protein expression.
Added value of this study
Our investigation is one of the very few existing studies focusing
on mismatch repair-proficient colorectal adenomas from Lynch
syndrome mutation carriers, with the aim to determine the roles
of DNA methylation changes and somatic mutations in cancer-
associated genes in such neoplastic lesions. We show that
tumor initiation may precede the loss of mismatch repair protein
and identify molecular alterations present in adenomas with
retained mismatch repair protein expression. While many of
these changes were more prevalent in mismatch repair deficient
adenomas, some were less frequent or even absent in the latter.
Specifically, we found that hypermethylation of IGF2, NEUROG1,
CDKN2A,CRABP1, SFRP1, and SFRP2, and especially KRASmu-
tations may accelerate, or possibly initiate, Lynch syndrome-
associated tumorigenesis when the wild-type allele of the predis-
posing mismatch repair gene is still present as judged from
retained protein expression. The emerging differences between
mismatch repair deficient and proficient adenomas suggest that
tumorigenesis in Lynch syndromemay be driven by different path-
ways, as supported by recent findings from Lynch syndrome-
associated colorectal carcinomas.
Implications of all the available evidence
Recent studies, including this study, have shed light on the neo-
plastic process associated with colon tumorigenesis in Lynch syn-
drome. The fact that adenoma development is possible in the
absence of biallelic inactivation of the predisposing mismatch
repair gene shows that the traditional Knudson's two-hit mecha-
nism is not the only one that applies to mismatch repair gene
mutation-associated tumorigenesis. Genetic and epigenetic alter-
ations observed inmismatch repair proficient adenomasmay qual-
ify for alternative tumor-initiating or promoting events. The
findings have important clinical implications. As 27% of Lynch
syndrome adenomas from our investigation and up to 46% of ad-
enomas from published studies express the mismatch repair pro-
tein corresponding to the gene mutant in the germline, retained
mismatch repair protein expression in a colorectal adenoma can-
not be used to rule out Lynch syndrome in diagnostics. Genetic
and epigenetic changes detected in mismatch repair proficient ad-
enomasmay provide potential biomarkers of increased tumor risk.
Genetic heterogeneity in Lynch syndrome adenomas and carcino-
mas may be relevant for the design of targeted therapies or pre-
ventive measures. Larger sample sizes are required to confirm
the recent findings described above and the specific contributions
of the observed alterations to tumorigenesis. Further investiga-
tions are also needed to explore the extent to which the findings
from Lynch syndrome may apply to sporadic colorectal
tumorigenesis.
281S. Mäki-Nevala et al. / EBioMedicine 39 (2019) 280–291protein [9–13], andMMRdeficiency is associatedwith larger polyps and
higher grade [10,14,15]. The nature, timing and order of othermolecular
hits driving the malignant transformation are yet to be identified.
Most LS CRCs exhibit microsatellite instability (MSI) caused by de-
fects in the MMR system [16]. CpG island methylation phenotype
(CIMP) characterized by aberrant CpG island methylation in promoters
of various tumor suppressor genes (TSGs) [17], is prevalent in LS CRC,
and occurs already at early stages of tumor development, but clearly in-
creases along with dysplasia [9]. The molecular drivers behind CIMP,
and its role in hereditary cancer remain obscure. Accumulation of so-
matic mutations involving the epigenetic regulatory genes may serve
as a mechanism for CIMP [8].
Long interspersed elements (LINEs) form a class of retrotransposons
that constitute approximately 17% of the human genome, and are nor-
mally heavily methylated [18]. In cancer, LINEs can be activated due to
DNA hypomethylation. LINE-1 hypomethylation serves as a surrogate
marker for global hypomethylation that can lead to chromosomal insta-
bility (CIN) [19]. LINE-1 is a 6 kb long retrotransposon that can, once ac-
tivated, induce transcription of other genes [18]. Moreover, activated
LINE-1 can change the epigenetic regulation of adjacent genes [20],
and can occur already at early stages in malignant transformation of
CRC [21,22].
The aimof this studywas to investigatemolecularmechanisms, DNA
methylation changes and somatic mutations, as events contributing to
LS-associated colorectal tumorigenesis. Our focus was on precursors of
cancer, adenomas, based on the observation by Valo et al. [9], that
many LS-associated adenomas retain the expression of the MMR pro-
tein corresponding to the germlinemutation. DNAmethylation changes
were investigated in eight CIMP marker genes, LINE-1, and seven
candidate TSGs associated with early colon tumorigenesis [23]. More-
over, adenomas were studied for somatic alterations in mutational
hotspots of 22 cancer-associated genes. DNA methylation changes and
mutations were compared between MMR-proficient (MMR-P) and
MMR-deficient (MMR-D) adenomas to identify possible initiating or
promoting molecular changes in adenomas in which the “second hit”
leading to the loss of MMR function had not (yet) occurred.
2. Materials and methods
2.1. Patient samples
Study material consisted of formalin-fixed, paraffin-embedded
(FFPE) specimens of normal mucosae, adenomas and carcinomas from
Table 1
Lynch syndrome individuals and eligible specimens.
No of patients or specimens






Normal colonic mucosa 29
Low dysplasia adenoma 47
High dysplasia adenoma 21
Carcinoma 25
Total 122
282 S. Mäki-Nevala et al. / EBioMedicine 39 (2019) 280–29157 LS patients (Table 1). Specimens were collected at the Helsinki Uni-
versity Central Hospital and the Jyväskylä Central Hospital during
2013–2016. All the patients were represented in the nationwide Hered-
itary Colorectal Cancer Registry of Finland, and the information of veri-
fied germline mutations is available in Supplementary Table S1. In this
study, we used normal mucosae and adenoma specimens, extending
the sample series fromour previous study [9]with 23 specimens includ-
ing 13 adenomaswith low-grade dysplasia, seven adenomas with high-
grade dysplasia and three carcinomas. Normal mucosae collected for
this study were supplemented with 13 older archival specimens of nor-
mal mucosae of Lynch syndrome patients to increase a total number of
the reference group (n=29). Tumor material was evaluated for histol-
ogy and tumor content by thepathologist. The detailed characteristics of
adenoma specimens are presented in Supplementary Table S2. Patients
whose adenoma specimens were used in this study were between 26
and 74 years old (mean 52·4 ± 2·9 CI 95%) at the time of biopsy. This
study was approved by the Institutional Review Board of the Central
Finland Health Care District (K\\S shp Dnro4/2011) and the collection
of archival specimens by the National Authority for Medicolegal Affairs
(Dnro 1272/04/044/07) and the National Supervisory Authority for
Welfare and Health (Valvira, Dnro 10,741/06.01.03.01/2015).
2.2. DNA extraction
DNA extraction from FFPE samples was performed by the phenyl-
chlorophorm method [24]. DNA concentrations were measured by the
Nanodrop spectrophotometer (Thermo Fisher Scientific). Additionally,
DNA samples from adenoma specimens were quantified by the
Qubit™ Fluorometer (Thermo Fisher Scientific), and these values were
used in the next generation sequencing (NGS) protocol.
2.3. Immunohistochemical (IHC) staining for MMR protein expression
IHCwas done according to the standard procedures using the prima-
ry antibodies described previously [9,25].
2.4. Microsatellite instability (MSI) analysis
Mononucleotide repeat markers BAT25 and BAT26, which have been
shown to sensitive and specific markers of high-degree MSI (MSI-H)
[26,27], were used to study MSI status. When either one of the markers
was unstable, a tumor was considered MSI, and if both markers were
normal a tumor was considered microsatellite-stable (MSS).
2.5. Methylation assay by methylation-specific multiplex ligation-
dependent probe amplification (MS-MLPA)
The MS-MLPA was used to study DNA methylation changes in the
promoters of eight CIMP-associated genes, seven selected candidate
TSGs, and LINE-1, according to the manufacturer's instructions (MRC
Holland, Amsterdam, The Netherlands). The method is described inmore detail in Valo et al. [9] Briefly, 150–250 ng of DNA was used for
each reaction. MS-MLPA is based on the hybridizing probes including
the recognition sequence of GCGC for the methylation-sensitive endo-
nuclease HhaI. Methylation prevents digestion reaction to occur, and
after the PCR amplification a signal peak appears if template DNA is
methylated [28]. Methylation dosage ratios (Dm) were calculated by
the following formula: Dm = (Px/Pctrl)Dig / (Px/Pctrl)Undig, where Dm is a
methylation dosage ratio (degree of methylation), Px is a peak area of
the given probe, Pctrl is a sum of the peak area of all control probes, Dig
stands for sample digestedwithHhaI, andUndig stands for the undigest-
ed sample. The average degree of methylation (Dm) plus one standard
deviation or two standard deviations (i.e. stringency level II that was
used for the CIMP analysis for themore accurate classification) calculat-
ed for normal mucosae samples determined a threshold value for the
hypermethylation for each probe. In tumor samples, probes were de-
fined methylated, if the degree of methylation exceeded the threshold
value. The results from individual tumor samples were combined to de-
fine the relative frequency of hypermethylation.
CIMP status was investigated using the SALSA MLPA probemix
ME042-B2 (MRC Holland) including 3–6 probes for the promoter of
each marker gene: CACNA1G, IGF2, NEUROG1, RUNX3, SOCS1, CDKN2A,
MLH1 and CRABP1. The gene was considered methylated when one
fourth or more of the probes were methylated [29]. The tumor sample
was classified CIMP(+) using the Weisenberger panel: three or more
genes out of CACNA1G, IGF2, NEUROG1, RUNX3 and SOCS1 should be
methylated [30].
LINE-1 hypomethylation was studied by the custom-made LINE-1-
MS-MLPA assaydescribed in Pavicic et al. [31] Briefly, the assay included
in total of ten probes, of those three were methylation-sensitive probes
targeting regions with the HhaI restriction site inside the LINE-1 pro-
moter sequence. The remaining seven probes provided a set of control
probes targeting other regions without the restriction site in the LINE-
1 sequence. LINE-1 hypomethylation was calculated based on L1-M2
probe [31].
Similarly, the custom-made MS-MLPA panel was designed to study
promoter methylation of the selected candidate TSGs involved in early
colon tumorigenesis in a mouse model for LS: DKK1, SFRP2, CDH1,
HOXD1, SFRP5, SLC5A8, and SFRP1 [23]. Detailed design is described in
Valo et al. [9] The custom-made probeswere used togetherwith the ref-
erence probemix of the SALSAMLPA P300-A2HumanDNAReference-2
(MRC Holland).
2.6. Amplicon-based next generation sequencing (NGS)
In total of 63 DNA samples of FFPE adenoma specimenswere eligible
for the sequencing study. Libraries were prepared from 4 to 15 ng of
inputDNA according to themanufacturer's protocol of the Ion AmpliSeq
Library Kit 2.0 (Rev. C.0) (Thermo Fisher Scientific) using the Ion
AmpliSeq Colon and Lung Cancer Panel (Thermo Fisher Scientific). The
panel targets mutational hotspots in 22 genes totaling 14.6 kb: AKT1,
ALK, BRAF, CTNNB1, DDR2, EGFR, ERBB2, ERBB4, FBXW7, FGFR1, FGFR2,
FGFR3, KRAS, MAP2K1, MET, NOTCH1, NRAS, PIK3CA, PTEN, SMAD4,
STK11, and TP53. The libraries were purified using the AMPure XPmag-
netic beads (Beckman Coulter, Krefeld, Germany), and the quantifica-
tion was performed with the Qubit Fluorometer with the Qubit dsDNA
HS Assay Kit (Thermo Fisher Scientific). Library amplification and en-
richment steps were performed according to the manufacturer's proto-
col of the Ion PGM Hi-Q View OT2 Kit (Rev.C.0) (Thermo Fisher
Scientific) on the Ion OneTouch2 and Ion OneTouch ES instruments, re-
spectively (Thermo Fisher Scientific). Sequencing was performed using
the Ion PGMHi-Q View Sequencing Kit (Rev.C.0) on the Ion PGM 316v2
Chip (Thermo Fisher Scientific). The barcoded (Ion Xpress Barcode
Adapters, Thermo Fisher Scientific) libraries were pooled in the sets of
8–16 libraries.
The sequencing data were analyzed utilizing the Torrent Suite soft-
ware (v5.2.2). Coverage analysis was performed by using the plug-in
Table 2
The proportions of retainedMMR protein expression in adenomas and carcinomas by IHC
(extended series of the previous study [9]).













1/17 (6%) 0/2 (0%) 1/2
(50%)
2/21 (10%)
Carcinoma 0/15 (0%) 0/3 (0%) 0/5 (0%) 0/23 (0%)
a MMR IHC could not be performed on two carcinoma and one adenoma with low-
grade dysplasia specimens, and thus, they are missing from this table compared to the
numbers presented in Table 1.
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the variantCaller (v5.2.1.39). Default analysis parameters were applied
on signal processing, base calling, read alignment and variant calling.
Reads were aligned at the human genome reference assembly of
h19. Variant calling files were imported in the VarSeq software
(GoldenHelix) and annotated with the databases of COSMIC Cancer
Gene Census 71 [32], ExAC Variant Frequencies 0.3, dbSNP 149 (NCBI),
and RefSeq Genes 105 Interim v1 (NCBI), and in silico functional predic-
tion tools (SIFT, PolyPhen2 HVAR, MutationTaster, MutationAssessor,
FATHMM, and FATHMM MKL). For the final step of variant analysis,
only variants with quality score ≥ 30, read depth ≥ 50, and VAF ≥ 0·05
were considered true positives. Moreover, all variants mapped outside
the target regions, producing synonymous variant, or variants reported
in the 1000 Genomes project (NCBI dbSNP 149) and/or in the ExaC da-
tabasewithminor allele frequency (MAF) of 0·01 ormore, werefiltered
out.Normal – MMR-P NS NS 0·009 NS
Normal – MMR-D NS <0·0001 0·009 NS















CACNA1G IGF2 NEUROG1 RU
%
Normal (n = 29)
MMR-P (n = 12)
MMR-D (n = 42)
Normal – MMR-P NS 0·049 NS N
Normal – MMR-D NS <0·0001 NS N














DKK1 SFRP2 CDH1 H
%
Normal (n = 29)
MMR-P (n = 15)
MMR-D (n = 43)
a
b
Fig. 1. Frequencies of methylated genes in normal colon, and MMR-P and MMR-D adenoma sp
positive phenotype. b. Hypermethylation frequencies of candidate tumor suppressor gen
Abbreviations: MMR-D, MMR deficient; MMR-P, MMR proficient; NS, non-significant.2.7. Statistical analysis
Statistical analyses were performed using the SPSS software, version
24.0 (IBM SPSS Inc., Chicago, IL, USA). Group-wise comparisons for cat-
egorical variables were calculated by using the Fisher's exact-test. For
continuous variables, normal distribution was tested by Shapiro-Wilk
test, and a parametric (Student's t-test or one-way ANOVAwith Tukey's
post hoc test, homogeneity of variances tested by Levene's test) or non-
parametric (Mann-Whitney U test/Kruskal-Wallis one-way ANOVA)
test was used, as appropriate. Two-sided p values b0·05 were consid-
ered significant. The Bonferroni correction method was applied on p
values obtained from multiple comparisons.
2.8. Data sharing statement
All relevant data supporting this study is published along the paper.
Case-specific DNA methylation data is available upon request.
3. Results
3.1. MMR protein expression and MSI status
The colorectal specimen collection described in Table 1 was used for
IHC investigations to evaluate if the remaining wild-type allele of the
germline mutated MMR gene had undergone somatic inactivation. Pro-
tein expression of the relevant MMR genes was lost in all carcinomas
(Table 2). Among adenomas, 35% (16/46) of low dysplasia cases and
10% (2/21) of high dysplasia cases retained the protein expression of
the predisposing MMR gene (Table 2). Normal mucosae (n= 43) were
tested previously and all showed normal MMR protein expression [9].NS NS NS NS NS
NS NS NS 0·045 NS















NX3 SOCS1 CDKN2A MLH1 CRABP1 CIMP(+)
S NS NS <0·0001
S NS NS <0·0001











OXD1 SFRP5 SLC5A8 SFRP1
ecimens. a. Hypermethylation frequencies of CIMPmarker genes and frequencies of CIMP












































Probe Normal – MMR-P Normal – MMR-D MMR-P – MMR-D Kruskal-Wallis p value
MLH1 III NS 0·060 NS 0·046
IGF2 I 0·005 <0·0001 NS <0·0001
IGF2 II NS 0·023 NS 0·028
IGF2 III 0·005 <0·0001 NS <0·0001
NEUROG1 I NS 0·021 NS 0·017
NEUROG1 II NS 0·024 NS 0·016
NEUROG1 III NS 0·021 NS 0·026
NEUROG1 IV NS 0·008 NS 0·009
NEUROG1 VI 0·047 NS NS 0·045
CDKN2A IV 0·028 0·001 NS 0·001
CRABP1 III 0·040 NS NS 0·034



































Fig. 2.Comparison of the averagedegrees ofmethylation innormal colon, andMMR-P andMMR-Dadenoma specimens. a. The CIMPprobes showing statistical significance (p b 0·05)with
Kruskal-Wallis test. b. Average degree of methylation of SFRP1. c. Average degree of methylation of SFRP2. Bonferroni corrected two-sided p values b0·10 are presented for the pairwise
comparisons. Theupper and lower edges of the boxes are the 75th and 25th percentiles, the horizontal line inside the boxdenotes themedian, thewhiskers indicate thehighest and lowest
values, and the asterisks and open circles stand for outliers. Abbreviations: Dm, methylation dosage; MMR-D, MMR deficient; MMR-P, MMR proficient.
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and BAT26. We found a clear association between IHC and MSI status
(p b 0·0001). All tested carcinomas and all adenomas with absent
MMR protein showed MSI, with one exception of adenoma with low
dysplasia having stable microsatellites. All adenomas with intact MMR
protein expression forwhich enoughDNAwas available forMSI analysis(n = 11) were MSS. Throughout this paper, adenomas with absent
MMR protein or presence of MSI or both are considered MMR-
deficient (MMR-D, n = 49) and those with neither abnormality MMR-
proficient (MMR-P, n = 18).
The existence of significantMMR-proficient subsets of LS-adenomas
indicates the necessity of other somatic events to initiate malignant
285S. Mäki-Nevala et al. / EBioMedicine 39 (2019) 280–291transformation, leading us to investigate DNAmethylation changes and
somatic mutations in LS-associated adenomas (see below).
3.2. DNA methylation changes
3.2.1. CIMP markers
Methylation analysis of eight genes (CACNA1G, IGF2, NEUROG1,
RUNX3, SOCS1, CDKN2A, MLH1 and CRABP1) linked to CIMP was used
to assess the frequency of CIMP, a high-degree coordinatedmethylation
of CpG islands that are normally unmethylated. CIMP(+) was defined
according to the Weisenberger panel [30]. The frequency of CIMP(+)
increased along with the dysplasia grade, occurring in 0% (0/29), 11%
(4/37), 17% (3/18), and 45% (10/22) of normal mucosae, adenomas
with low-grade dysplasia, adenomas with high-grade dysplasia, and
carcinomas, respectively.
Altered methylation was evaluated in twoways, by determining the
frequencies of hypermethylated samples based on defined cut-off
methylation dosage (Dm) values for hypermethylation for each marker
gene with normal mucosa as a reference (see Materials and Methods)
and alternatively, by treating the degree of methylation (by Dm values)
as a continuous variable in the samples. Fig. 1a shows the frequencies of
hypermethylation for eight CIMP markers in adenomas stratified by
MMR status, with normal mucosae as a reference. Hypermethylation
frequency of NEUROG1 was increased already in MMR-P adenomas
compared to normal colon (p = 0·009), and methylation frequency
was higher than in MMR-D adenomas, although statistical significance
was not obtained between MMR-P and MMR-D cases. MMR-D adeno-
mas showed significantly elevated frequencies of hypermethylation rel-
ative to normalmucosa at IGF2 (p b 0·0001),NEUROG1 (p=0·009) and
CRABP1 (p = 0·045) loci. Among adenomas with MLH1 methylation
depicted in Figs. 1a and 2a, only one, a MMR-D adenoma with high-
grade dysplasia, revealed hypermethylation with the probe targeting
the promoter region “C” of MLH1 (MLH1-I probe); hypermethylation
of this region is associatedwith loss ofMLH1protein [33]. In the remain-
ing cases, other regions of the MLH1 promoter (MLH1-II, III, and IV
probes), not associated with protein expression, were involved.
When examining the average Dm values for the individual probes
contributing to each CIMP marker gene (Fig. 2a), at least one probe of
the following marker genes revealed a significant increase already in
MMR-P adenomas vs. normal colon: IGF2, NEUROG1, CDKN2A, and

























Fig. 3. Average degree of LINE-1 methylation. a. LINE-1 methylation levels in all the specime
adenoma specimens. Bonferroni corrected two-sided p values b0·10 are presented in the
horizontal line inside the box denotes the median, the whiskers indicate the highest and low
adenoma with high-grade dysplasia; AdLGD, adenoma with low-grade dysplasia; Dm, methylamethylation also in MMR-D adenomas vs. normal colon. There were
two probes, one for CRABP1 and one forNEUROG1, which showed signif-
icantly elevated methylation solely in MMR-P adenomas (vs. normal
colon).
3.2.2. Candidate tumor suppressor genes
We studied seven candidate TSGs (DKK1, SFRP2, CDH1, HOXD1,
SFRP5, SLC5A8, and SFRP1) associated with early colon oncogenesis
and being downregulated by promoter methylation in an experimental
mouse model for LS [23]. Similarly to CIMP marker analysis, we first
compared the hypermethylation frequencies of each gene in normal
colon, MMR-P and MMR-D adenomas. Here, both SFRP1 and SFRP2
showed significantly increased frequency of hypermethylation in both
MMR-P and MMR-D tumors compared to normal colon (Fig. 1b). Like-
wise, in the analysis of average Dm values, SFRP1 and SFRP2 showed in-
creased methylation levels in both MMR-P and MMR-D adenomas
compared to normal colon (Fig. 2b, c).
3.2.3. LINE-1
The average degree of methylation of LINE-1, amarker for global hy-
pomethylation, decreased along with dysplasia (p = 0·005) (Fig. 3a).
Statistically significant difference relative to normal colonwas observed
for carcinoma, but not for adenomas with high- or low-grade dysplasia,
suggesting that LINE-1 methylation is a rather late event in LS-
associated tumorigenesis. When comparing adenomas stratified by
MMR status with normal colon, significantly decreased methylation
level was observed for MMR-D adenomas (Fig. 3b), indicating that
LINE-1 hypomethylation is likely to occur after the loss of MMR protein.
4. Effect of dysplasia grade on methylation results
To produce the results given in Figs. 1–3, adenomas with high- and
low-grade dysplasia were combined. The same analyses were per-
formed on adenomas with low-grade dysplasia only and are available
in Supplementary Materials (Supplementary Fig. S1–S3). Adenomas
with high-grade dysplasia included too few MMR-P cases (Table 2)
and could not be studied as an independent group. As evident from Sup-
plementary Figs. S1–S3, the results remained essentially similar to those
derived from adenomas not stratified by dysplasia grade. Moreover, to
exclude the effect of dysplasia grade on the results, we compared ade-






















ns sorted by histology. b. LINE-1 methylation in normal colon, and MMR-P and MMR-D
figure. The upper and lower edges of the boxes are the 75th and 25th percentiles, the
est values, and the asterisks and open circles stand for outliers. Abbreviations: AdHGD,















































































































































249Ad P + MSS? LOW MLH1 7 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 1 0 1 0 3 missense mutation
686Ad P - MSS HIGH MSH6 2 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 nonsense mutation
264Ad P - MSS? LOW MLH1 2 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 in-frame deletion
670Ad P ND ND LOW MSH2 2 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 frameshift deletion
187Ad P - MSS LOW MSH6 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
248Ad P - MSS? LOW MSH2 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
268Ad P - MSS LOW MLH1 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
677Ad P - ND HIGH MLH1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
148Ad P - MSS LOW MLH1 0
164Ad P ND MSS? LOW MLH1 0
197Ad P ND ND LOW MLH1 0
259Ad P - MSS LOW MLH1 0
271Ad P - MSS LOW MLH1 0
672Ad P - ND LOW MSH6 0
690Ad P - ND LOW MLH1 0
693Ad P - MSS LOW MLH1 0
689Ad D - ND LOW MSH6 821311111102
101Ad D + MSI LOW MLH1 6112211151
260Ad D ND ND LOW MLH1 2132312151
151Ad D ND ND LOW MLH1 311121101
261Ad D ND ND HIGH MLH1 12121119
100Ad D + MSI HIGH MLH1 21137
169Ad D - MSI HIGH MLH1 4 1111
170Ad D - MSI HIGH MLH1 2 11
270Ad D - MSI HIGH MLH1 112
674Ad D - MSI HIGH MLH1 112
680Ad D - MSI LOW MLH1 2 1 1
685Ad D - MSI LOW MLH1 2 1 1
695Ad D - MSI LOW MSH2 112
247Ad D - MSI HIGH MSH2 1 1
265Ad D - MSI HIGH MLH1 11
272Ad D - MSI HIGH MLH1 11
671Ad D ND MSI HIGH MSH2 1 1
682Ad D - ND HIGH MLH1 11
106Ad D - MSI LOW MLH1 1 1
168Ad D - MSI LOW MLH1 1 1
171Ad D - MSI LOW MLH1 1 1
256Ad D + MSI LOW MLH1 1 1
258Ad D - MSI LOW MSH2 1 1
266Ad D + MSI LOW MLH1 11
684Ad D - ND LOW MLH1 1 1
165Ad D - MSI HIGH MLH1 0
253Ad D - MSI HIGH MLH1 0
263Ad D - MSI HIGH MLH1 0
679Ad D ND ND HIGH MLH1 0
687Ad D - MSI HIGH MSH6 0
160Ad D - MSS LOW MSH2 0
188Ad D - MSI LOW MSH6 0
195Ad D - MSI LOW MLH1 0
196Ad D - MSI? LOW MLH1 0
250Ad D - MSI LOW MLH1 0
251Ad D - MSI LOW MSH2 0
252Ad D - MSI LOW MLH1 0
254Ad D - MSI LOW MLH1 0
255Ad D - MSI LOW MLH1 0
257Ad D - MSI? LOW MLH1 0
675Ad D - MSI LOW MLH1 0
691Ad D - MSI LOW MLH1 0
692Ad D - MSI LOW MLH1 0
Total (n = 59) 1.7 8.5 15.3 1.7 10.2 3.4 5.1 8.5 1.7 3.4 1.7 22.0 1.7 1.7 5.1 10.2 18.6 3.4 23.7
5.215.213.63.133.63.65.21)61=n(P-RMM
MMR-D (n = 43) 2.3 11.6 16.3 2.3 11.6 4.7 7.0 9.3 2.3 4.7 18.6 2.3 2.3 4.7 14.0 20.9 4.7 28.0
AdLGD (n = 41) 2.4 9.8 9.8 2.4 12.2 2.4 4.9 9.8 2.4 2.4 19.5 2.4 2.4 4.9 9.8 19.5 4.9 19.5
3.337.611.116.58.726.56.56.56.56.58.726.5)81=n(DGHdA
Fig. 4.Mutation status of adenomas stratified by theirMMR status and number of mutations. Mutations presented in this table are reported in the COSMIC database (v71). Numbers in the
colored cells indicate the number of mutations affecting a given gene in the sample in question, and color distinguishes the type of mutation. Table below shows mutation frequencies in
adenomas stratified by MMR status or dysplasia grade. Note: question mark after MSI or MSS status indicates that only one probe produced an interpretable result (for MSS?) or due to
poor quality, the result was weakly interpretable (MSI?). Abbreviations: AdHGD, adenoma with high-grade dysplasia; AdLGD, adenoma with low-grade dysplasia; CIMP, CpG island
methylator phenotype; D, deficient; MMR, DNA mismatch repair; MMR-D, MMR deficient; MMR-P, MMR proficient; ND, not done; P, proficient.
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(data not shown).
4.1. Somatic mutations
Adenomas were studied for somatic mutations targeting the muta-
tional hotspots in 22 cancer-associated genes (see Materials and
Methods). As the amount of sample material of adenoma specimens
was limited, this panel served as an excellent option to study somatic
mutations even in those samples with a very low DNA content. In
total, 59 out of initial 63 samples that were eligible for the sequencing
study produced good quality sequencing library and sequencing results,
including 16 MMR-P adenomas, out of which a majority (n=14) wereadenomas with low-grade dysplasia. For the obtained sequencing data,
mean values for the read depth, the mapping uniformity between the
amplicons, and the percentage of reads mapped on targets were 1379
(± 176 CI 95%), 94% (± 2 CI 95%), and 92% (± 1 CI 95%) respectively.
Here, we present non-synonymous mutations that have previously
been reported in the COSMIC database [32], emphasizing their cancer-
associated nature. The most frequently mutated genes were TP53,
followed by KRAS, SMAD4, and CTNNB1, found in 24% (n = 14), 22% (n
= 13), 19% (n = 11), and 15% (n = 9) of the adenomas, respectively.
Overall, 54% (32/59) of adenomas harbored at least one mutation. One
MMR-P sample (249Ad) included clearly more mutations (n = 7)
than other MMR-P adenomas (Fig. 4). This particular case was the
only CIMP(+) MMR-P adenoma. In total, there were five CIMP(+)
Table 3















73 148Ad LOW MLH1 c.1731 +
2247_1897-402del
(Mutation 1)
IGF2 None None MSS (−)
3 164Ad LOW MLH1 c.1731 +
2247_1897-402del
(Mutation 1)
ND ND None MSSa ND
16 187Ad LOW MSH6 c.900dup NEUROG1 SFRP1 CTNBB1 p.Ser45Phe (37) MSS (−)
95 197Ad LOW MLH1 c.1731 +
2247_1897-402del
(Mutation 1)
ND SFRP1 None ND ND
13 248Ad LOW MSH2
c.1667_1671del
CDKN2A SFRP2, SLC5A8, SFRP1 KRAS p.Gly12Asp (7) MSSa (−)
17 249Ad LOW MLH1 c.546-2A N G MLH1, IGF2,
NEUROG1,
CDKN2A, CRABP1
SFRP2, HOXD1, SFRP1 EGFR p.Ala767Val (5), KRAS p.Gly12Val (8), PIK3CA p.Arg693His
(5), SMAD4 p.Pro514Ser (5), TP53 p.Arg282Trp (6);
p.Pro250Leu (5); p.Gly244Ser (5)
MSSa (+)
45 259Ad LOW MLH1 c.1731 +
2247_1897-402del
(Mutation 1)
NEUROG1 SFRP2, SFRP1 None MSS (−)





SFRP1 KRAS p.Gly12Val (29), SMAD4 p.Pro102Leu (18) MSSa (−)






none CTNNB1 p.Thr41Ala (5) MSS (−)
101 271Ad LOW MLH1 c.1731 +
2247_1897-402del
(Mutation 1)
none SFRP1 None MSS (−)
12 670Ad LOW MSH2
c.1552_1553_del
ND SFRP2, CDH1, HOXD1,
SLC5A8, SFRP1
FBXW7 p.Arg465His (7), KRAS p.Ala146Thr (10) ND ND
16 672Ad LOW MSH6 c.900dup ND SFRP2, CDH1, HOXD1,
SLC5A8, SFRP1
None ND ND
73 677Ad HIGH MLH1 c.1731 +
2247_1897-402del
(Mutation 1)
None SFRP2, SFRP1 None ND (−)




SFRP2, SLC5A8, SFRP1 KRAS p.Ala146Thr (45), TP53 p.Glu180Lys (5) MSS (−)
120 690Ad LOW MLH1 c.1731 +
2247_1897-402del
(Mutation 1)
None SFRP2, CDH1, HOXD1,
SOCS1, SLC5A8, SFRP1
None ND (−)









Abbreviations: CIMP, CpG islandmethylator phenotype;MSS,microsatellite stable;MSI,microsatellite instable; ND, not done; TSGs, tumor suppressor genes; VAF, variant allele frequency.
a Only one of the two microsatellite markers produced an interpretable result.
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genes (Fig. 4). A vast majority of the mutations were missense
mutations (Fig. 4). The full list of our COSMIC mutations is available in
Supplementary Table S3.
We observed a somewhat higher average number of mutations in
MMR-D adenomas compared to MMR-P adenomas (2·4 vs. 1·0), al-
though no statistical difference was found (p=0·323). As themost in-
triguingfinding, KRASmutationswere clearlymore prevalent inMMR-P
adenomas (Fig. 4) (5/16, 31% vs. 8/43, 19%), although the difference is
statistically non-significant. Considering only KRASmutations in the co-
dons 12, 13, 61, or 146 regarded pathogenic [34–36], these were clearly
more prevalent in MMR-P tumors (5/16, 31% vs. 7/43, 16%). The obser-
vation remained the samewhen only adenomaswith low-grade dyspla-
sia were included: the frequency of pathogenic KRAS mutations was
29% (4/14) in MMR-P cases vs. 15% (4/27) in MMR-D cases. Detailed
molecular characteristics of MMR-P adenomas are presented case by
case in Table 3.
Mutational frequencies between adenomas with low-grade and
high-grade dysplasia were mostly similar, with no statistically signifi-
cant differences observed (Fig. 4). However, multiple genes, such as
BRAF (4/41, 10% vs. 1/18, 6%) and SMAD4 (8/41, 20% vs. 3/18, 17%)were slightly more frequently mutated in adenomas with low-grade
dysplasia than in tumors with high-grade dysplasia. Instead, mutations
in CTNNB1 (5/18, 28% vs. 4/41, 10%), KRAS (5/18, 28% vs. 8/41, 20%), and
TP53 (6/18, 33% vs. 8/41, 20%) occurred more often in advanced stage
adenomas.
One adenoma with low-grade dysplasia (256Ad) carried the BRAF
V600E mutation (VAF 5%). The BRAF mutation was the only mutation
detected in this specimen. Other BRAF missense mutations that were
found in four cases occurred in the codons 455, 467, and 469. The
BRAF V600E mutant tumor was characterized by MMR-D, CIMP(+),
MSI, and germline point mutation in MLH1 (c.543C N G). Moreover,
this tumor harbored hypermethylation inmultiple promoters, including
all three probes of IGF2, two probes of NEUROG1, one CRABP1, all three
probes of RUNX3, SFRP1, HOXD1, and SFRP2.
We also addressed themutation signatures by Alexandrov et al. [37],
taking the MMR deficiency related signature 6 as a reference. The adja-
cent bases for single base pair substitutionswere determined andmuta-
tion patterns constructed for adenomas based on the relative
frequencies of mutation types among all mutations found (Fig. 5a, b).
In this analysis, in addition to the COSMIC mutations, we also included
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Fig. 5. Distributions of different mutation types. a. Relative frequencies of different mutation types among all mutations found in all adenomas. b. The difference of relative mutation
frequencies between MMR-D and MMR-P adenomas (MMR-D – MMR-P). In a. and b., orange color indicates that a mutation type occurs exclusively in MMR-P adenomas, whereas
gray color indicates exclusive occurrence in MMR-D adenomas, and blue color indicates mutation types present in both MMR-P and MMR-D tumors. c. Frequency of KRAS mutations
and mutation patterns in MMR-P and MMR-D adenomas. Abbreviations: MMR-D, MMR deficient; MMR-P, MMR proficient.
288 S. Mäki-Nevala et al. / EBioMedicine 39 (2019) 280–291Methods), although not found in the COSMIC database. The full list of
the mutations used in this analysis is available in Supplementary
Table S3. Based on the total of 310 missense or nonsense mutations,
the following observations were made. C N T transitions were clearly
the most prevalent substitutions in both MMR-P and MMR-D adeno-
mas. However, there were some differences in base triplets harboring
the transitions. Signature 6 is characterized by C N T transitions at
NpCpG sites [37], thus, we investigated the frequencies of these muta-
tions among all mutations found in MMR-P and MMR-D adenomas. In-
deed, they were more prevalent in MMR-D adenomas (53/277, 19% vs.
3/33, 9%), although statistical significancewas not reached. Intriguingly,
the mutation with the highest probability to occur in MMR-D tumors
according to the mutation signature, C N T at GpCpG, was missing in
MMR-P adenomas (0/16), but was present (12/43, 28%) in MMR-D ad-
enomas (p = 0·025). Moreover, we observed ApCpC, CpCpC, and
GpTpA sites to be enriched with mutations in MMR-P adenomas com-
pared toMMR-D adenomaswith N5% difference in the relativemutation
frequency. Signature 6 is characterized also by small indels, but in
our study, only three deletions (1–3 bp) were found, all in MMR-D
adenomas.
In addition, we examined pathogenic KRAS mutations (codons 12,
13, 61, and 146) that can cause constitutive activation of KRAS protein
[34,35], and all possible mutations based on the flanking nucleotides
(Fig. 5c). KRAS G13D mutations (n = 4) occurred exclusively in MMR-
D adenomas, in agreement with published findings of this mutation
being associated with MSI tumors [38,39]. Codon 12 and 146mutations
were more prevalent in MMR-P adenomas (see Discussion).
5. Discussion
In the majority of colorectal cancers, the adenoma-carcinoma se-
quence is a well-established path, where adenomatous polyps have ahigh risk of developing into carcinomas. However, in LS, recent findings
such as frequent development of colorectal cancer despite regular
colonoscopic surveillance to remove adenomas has challenged the
classical view [40]. Furthermore, the tumorigenic stage at which MMR
deficiency appears is controversial. Observations of MMR protein loss
associated with high-grade dysplastic and larger polyps supports defi-
cient MMR being a late event (this study and [10,13–15,41]). However,
the discovery of histologically normal colonic crypts with a loss of MMR
protein expression, i.e. MMR-deficient crypt foci (MMR-DCF) [42,43], as
well as a recent finding of MMR-deficiency preceding adenoma forma-
tion in LS suggest early appearance ofMMRdeficiency [44]. In our inves-
tigation, all LS carcinomas showed a complete loss of the MMR protein
expression, whereas 10% of adenomas with high-grade dysplasia and
35% adenomas with low-grade dysplasia maintained the expression,
implying that MMR protein loss occurs relatively late. Ahadova
et al. [38] proposed a model of three different pathways driving
LS-associated tumorigenesis, which could reconcile the contradictory
findings of the adenoma-carcinoma sequence and the timing of MMR-
deficiency. The model covers late appearance of deficient MMR
(MMR-P adenoma with secondary MMR inactivation) as well as early
MMR deficiency (MMR-DCF evolving into carcinoma either via MMR-
D adenoma or directly without any polyp precursor).
Only limited information is available of molecular alterations pres-
ent in LS adenomas lacking MMR deficiency as an obvious driver of tu-
morigenesis (MMR-P adenomas). We addressed DNA methylation
changes and somatic mutations of cancer-associated genes as possible
cancer-initiating or promoting events. Methylation was studied for
eight CIMP markers, seven selected candidate TSGs [23], and LINE-1.
The frequency of CIMP(+) and the average degree of LINE-1 hypome-
thylation increased with the degree of dysplasia. In general, they were
rather rare events in adenomas with low-grade dysplasia or in MMR-P
adenomas, indicating that wide-spread hypo- and hypermethylation
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mas revealed significantly elevated methylation levels (expressed as
average Dm values) relative to normal mucosa in four CIMP marker
genes: IGF2, CRABP1, NEUROG1, and CDKN2A (Fig. 2a) and the candi-
date TSGs SFRP1 (Fig. 2b) and SFRP2 (Fig. 2c) Our findings from LS
adenomas are supported in the sporadic context by Ibrahim et al.
[21] They recognized hypermethylation of NEUROG1 and SFRP2 as
early events in sporadic colorectal carcinogenesis, with NEUROG1
being hypermethylated in hyperplastic polyps and SFRP2 in adeno-
matous polyps. Moreover, in our previous study comparing LS indi-
viduals without vs. with colorectal cancer, SFRP1 hypermethylation
occurred as a “field defect” in high-risk normal mucosa from the lat-
ter group [9]. The baseline level of LINE-1 methylation may vary ac-
cording to the clinical category of colorectal cancer [31,45].
Progressive LINE-1 hypomethylation from normal mucosa to adeno-
ma to carcinoma accompanies both LS-associated (Fig. 3a) and spo-
radic colon tumorigenesis [22].
We used a sensitive technique (amplicon-based next-generation se-
quencing) to screen the hotspot regions of 22 established cancer-
associated genes for somatic mutations in LS-adenomas. Variant alleles
occurring with 5% or higher frequencies were considered. Mutations
were somewhatmore prevalent inMMR-D thanMMR-P adenomas (av-
erage 2·4 vs. 1·0 mutations per sample, statistically non-significant).
Additionally, MMR status of the adenomas was reflected in the base
substitution and sequence context-basedmutational signatures defined
by Alexandrov et al. [37] so that the MMR-deficiency-associated signa-
ture 6 was overrepresented among MMR-D adenomas, especially C
N T at GpCpG with a statistically significant difference, whereas ApCpC,
CpCpC, and GpTpA sites were enriched with mutations in MMR-P ade-
nomas (Fig. 5b). Previous studies have shown that targeted capture
and sequencing data can successfully be used to determine mutational
signatures [46]. However, the differences we report in mutation spectra
must be interpreted with caution, as we targeted solely mutational
hotspots in a limited number of genes, and the number of MMR-P
cases was relatively modest. Chang et al. [47] used RNA-seq data to de-
termine mutation profiles in 19 LS-associated (adenomatous) polyps.
16 (84%) were non-hypermutated and MMR-proficient except one,
whereas three (16%)were hypermutated, MMR-deficient and exhibited
signature 6 by Alexandrov et al. [37] Regardless of mutation rates, all LS
polyps displayed immune activation, the mechanism of which
remained unknown. A tumorigenic model was hypothesized in which
immune deregulation constitutes one of the earliest steps and precedes
the accumulation of genomic alterations.
The most frequently mutated genes in our study were TP53, KRAS,
SMAD4, and CTNNB1, in decreasing order (Fig. 4). While TP53mutations
are considered rare in MSI LS tumors [38,39], such mutations occurred
in up to one third of our LS adenomas (Fig. 4). The frequency of TP53
mutations in MMR-P adenomas or adenomas with low-grade dysplasia
was 13% and 20%, respectively. Commonly, TP53 mutations have been
associatedwith advanced CRC tumors [48], but recently, TP53mutations
were found already at early dysplastic stage in sporadic colorectal ade-
nomas [49]. Intriguingly, we found a higher prevalence of pathogenic
KRAS mutations in MMR-P than MMR-D adenomas (Fig. 4). Codon 12
mutations (especially G12V) are proposed to be associated with MSS
CRC [38,39] andMMR-P tumors [38],which is concordantwith ourfind-
ing (Fig. 5c). Besides G12V, KRAS A146T mutation occurred more often
in MMR-P than MMR-D adenomas in our investigation, whereas in the
study by Kloth et al. [39] focusing on verified or suspected LS patients,
A146T was associated with MSI tumors.
Our finding of a BRAF V600E mutation positive (MMR-D) adenoma
(case 256Ad in Fig. 4) is significant since BRAFV600Emutation generally
argues against LS [50].Wenote that the variant allele frequencywas low
(5%), and confirmation by immunohistochemical methods [25] was not
possible since there was no adenoma tissue left. At least four additional
tumors from germline carriers of MMR gene mutations have been re-
ported to carry BRAF V600E to date [50], together with our observationemphasizing that BRAF V600E mutation in a colorectal tumor is not an
absolute indicator to exclude LS in a diagnostic practice.
The suggestion that LS tumorigenesis may proceed along different
pathways is supported by a recent study by Binder et al. [51] who
found two major molecular subgroups of LS-CRCs, one resembling spo-
radicMSI CRC and another one sporadicMSS CRC, with respect tomuta-
tion spectra and microsatellite length distributions. Furthermore, the
mutation spectra suggested differences in DNA methylation between
the two groups [51]. Integrated analysis of genomic and transcriptomic
alterations has revealed extensive pathway sharing between
hypermutated andnon-hypermutated colorectal carcinomas; for exam-
ple, Wnt signaling is overactive in above 90% of all tumors via APC inac-
tivation or CTNNB1 activation [52]. Sekine et al. [44] compared APC
mutation profiles in MMR-P and MMR-D adenomas from LS patients
and found that frameshift mutations affecting repeat sequences
accounted for a major share of all APC mutations in MMR-D adenomas
but were rare in MMR-P adenomas, suggesting that MMR deficiency
generally precedes APC inactivation and adenoma formation. On the
other hand, Homfray et al. [53] compared APCmutation profiles in spo-
radic colorectal cancers with vs. without MSI, and the lack of essential
differences led the authors to conclude that APC mutations occur prior
to MMR inactivation. The gene panel we used did not include APC but
did include the CTNNB1 gene, mutations of which were recently linked
to immediate invasive growth, possibly explaining interval cancers in
LS [54]. Mutation frequencies of CTNNB1 did not differ between MMR-
P (13%) and MMR-D adenomas (16%) (Fig. 4).
A possibility remains that some MMR-P adenomas arising in LS pa-
tients are sporadic. Mutation frequencies in our MMR-P adenomas for
the four commonly affected genes discussed above (TP53, KRAS,
SMAD4, and CTNNB1) were comparable to those reported for sporadic
colorectal adenomas in the literature [49,55]. However, MMR-P and
MMR-D adenomas were diagnosed at similar ages, between 26 and 70
(mean51·4±3·0CI 95%) years forMMR-P adenomas (n=18) andbe-
tween31 and 74 (mean52·8±2·8 CI 95%) years forMMR-D adenomas
(n=47, age information unavailable for two cases), providing no obvi-
ous reason to suspect a higher proportion of sporadic cases in theMMR-
P group. In addition, it is important to note that MMR genes have many
other anti-carcinogenic functions beyond MMR and these functions
may be even more sensitive to reduced levels of MMR gene product
than the repair function. Cell line studies by Cejka et al. [4] revealed
that MMR proficiency was restored at low concentrations of MLH1,
whereas checkpoint activity required a full complement of MLH1 pro-
tein. Our recent results from Mlh1+/− mice showed normal Mlh1 pro-
tein expression and absence of MSI in colorectal carcinomas that
developed in these animals [56]. Instead of MSI, the tumors revealed
signs of chromosomal instability, consistent with decreased mRNA
expression of Mlh1 and several other chromosomal segregation-
associated genes in normal mucosa.
In summary, the presence of a strong predisposing defect (inherited
MMR gene mutation) in every cell but the absence of tumor develop-
ment until additional hits (to the predisposing MMR gene and other
genes) occur in a target tissue, makes LS a valuable model to dissect
the multistep tumorigenesis of colon and other organs. Our finding of
MMR-P adenomas shows, first, that tumor formation in LS is possible
even in the absence of a second hit to inactivate the wild-type allele of
the predisposing MMR gene. Second, we identify possible alternative
events prevalent in MMR-P adenomas that may serve as early alter-
ations accelerating, or possibly initiating, LS-associated tumorigenesis
when MMR protein expression is still intact. Hypermethylation of
IGF2, NEUROG1, CDKN2A, CRABP1, SFRP1, and SFRP2, and especially
KRASmutations may represent such events. Third, the emerging epige-
netic and genetic differences between MMR-P and MMR-D adenomas
imply the existence of different alternative routes to cancer develop-
ment in LS, consistent with observations of genetic heterogeneity in LS
carcinomas as discussed above. Further studies with large sample
sizes are necessary to deepen the understanding of tumorigenic
290 S. Mäki-Nevala et al. / EBioMedicine 39 (2019) 280–291sequences leading to LS cancers, thereby improving early recognition of
increased tumor risk and cancer prevention in LS.
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